Endo once more agrees to delay FDA litigation
September 24, 2018 at 12:11 PM EDT
The pharmaceutical company is challenging FDA policy on compounding, which could negatively impact an Endo blood pressure medicine.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.